Ureteral Stent-related Pain and Mirabegron (SPAM) Trial

Phase 4CompletedNCT02095665

Nova Scotia Health Authority22 enrolled

Overview

Ureteric stents are used often following ureteroscopy for prevention of obstruction from edema and or stone fragments. They are often associated with pain, voiding often, the need to urinate quickly and finding blood in the urine called "lower urinary tract symptoms" or LUTS for short. There is randomized studies showing the efficacy of α-blockers such as tamsulosin in relieving "stent symptoms" (pain and LUTS). There is emerging but limited evidence to show that antimuscarinic medications, used to treat overactive bladder (OAB) have some efficacy in decreasing stent symptoms. Mirabegron is a beta-agonist used to decrease OAB symptoms. Mirabegron functions to mediate relaxation of the detrusor muscle and has been useful in treating OAB symptoms. Conventional antimuscarinic medications often have bothersome side effects like dry mouth, constipation, blurred vision and cognitive impairment. This may limit their use in some populations. Mirabegron is well-tolerated with a good safety profile and therefore may be useful in treating stent symptoms without the bothersome side effects commonly seen with antimuscarinic medications. . The investigators hypothesize that mirabegron is effective in decreasing ureteral stent related LUTS and pain.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Nephrolithiasis

Interventions

MirabegronDRUG

50 mg of Mirabegron daily from stent insertion until removal 5 to 10 days

TamsulosinDRUG

0.4 mg of Tamsulosin daily and 1 tab of Percocet every 4 hours as necessary from stent insertion until removal 5 to 10 days

Tylenol #3DRUG

1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥18 years * First presentation for ureteroscopy for this particular stone * Planned insertion of double J ureteral stent * Planned ureteral stenting ≥5 days * Follow-up conducted at the Queen Elizabeth II Health Sciences Centre Exclusion Criteria: * Bilateral ureteral stents to be inserted * Stent already in situ prior to ureteroscopy * Patients with congenital renal abnormalities (ie: horseshoe kidney, ectopic kidney, etc) * Patients with urinary diversion * Patients with a history of interstitial cystitis/painful bladder syndrome, chronic prostatitis, or neurogenic bladder * Indwelling foley catheter * Active urinary tract infection * Patients currently taking antimuscarinics, mirabegron, or α-blockers * Patients with contraindications to receiving either mirabegron or tamsulosin (ie: urinary retention, end-stage renal disease, orthostatic hypotension, uncontrolled hypertension, known QT prolongation, severe aortic regurgitation), significant cognitive impairment, pregnancy, and active urinary tract infection * Planned upcoming elective cataract surgery * Suspected or confirmed ureteral perforation

Outcomes

Primary Outcomes

Ureteral stent related pain and lower urinary tract symptoms (LUTS) as measured by the Ureteral Stent Symptom Questionnaire.

The primary objective of this study is to determine if mirabegron is effective in decreasing ureteral stent related lower urinary tract symptoms (LUTS) following ureteroscopy for urolithiasis when compared to tamsulosin alone and in combination. Utilizing the Ureteral Stent Symptom Questionnaire, a self-administered questionnaire participants will report their urinary symptoms for comparison, enabling the comparison through out the different treatment arms.

Time frame: Measured twice, once at the time of surgery when stent is inserted and secondly at the time the stent is removed which will occur 5 to 10 days following surgery.

Secondary Outcomes

Quality of life impact of mirabegron for stent symptoms as measured with the Ureteral Stent Symptoms Questionnaire.

The secondary objectives are to determine if mirabegron is effective in decreasing ureteral stent related pain compared to tamsulosin alone and in combination following ureteroscopy for urolithiasis, determining if there are any improvements in health related quality of life (HRQoL). Subjects will maintain a diary recording the frequency of pain medication through out the period the stent remains insitu, 5 to 10 days.

Time frame: Measured twice, once at the time of surgery when stent is inserted and secondly at the time the stent is removed occuring 5 to 10 days later.